“Companies are realizing that investing stateside can provide more control and resilience to the drug supply chain,” says Dymowski. She cites political tensions, import and export disruptions, and ...

Bain Capital said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses ...

Exo-Top was established under the jurisdiction of the State of Nevada. Basing Exo-Top in the U.S. offers key advantages, including proximity to strategic partners, access to a robust biopharma ...

Jabil has acquired contract development and manufacturing organisation (CDMO) Pharmaceutics International (Pii) to offer support for drug development customers. The acquisition of Pii enhances Jabil's ...

APAC offers stability in an increasing challenging global geopolitical environment for clinical stage drug development.

“So, we need to increase efficiency on the process development side. While automation is one way of doing that, a much more efficient solution is to use in silico process development data to increase ...

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB ...

At Texas A&M University, one research lab is changing the game of droplet microfluidics, a technique that involves conducting ...

With continued investment and growing buzz from the industry, the AI hype is expected to extend through 2025 and beyond.

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...